Cargando…

Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy

The paradoxical role of reactive oxygen species in cell death versus cell survival establishes a delicate balance between chemotherapy efficacy and management of detrimental side effects. Normal proliferative signaling requires that cells remain inside a redox range that allows reversible protein ox...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, LeAnn C., Davis, Ryan R., Said, Naveen, Hollis, Thomas, Daniel, Larry W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767563/
https://www.ncbi.nlm.nih.gov/pubmed/29331665
http://dx.doi.org/10.1016/j.redox.2018.01.002
_version_ 1783292558144700416
author Rogers, LeAnn C.
Davis, Ryan R.
Said, Naveen
Hollis, Thomas
Daniel, Larry W.
author_facet Rogers, LeAnn C.
Davis, Ryan R.
Said, Naveen
Hollis, Thomas
Daniel, Larry W.
author_sort Rogers, LeAnn C.
collection PubMed
description The paradoxical role of reactive oxygen species in cell death versus cell survival establishes a delicate balance between chemotherapy efficacy and management of detrimental side effects. Normal proliferative signaling requires that cells remain inside a redox range that allows reversible protein oxidation to occur. Shifting the redox environment toward highly reducing or oxidizing states leads to cellular stress and cell death. Reactive oxygen species produced in response to Taxol and cisplatin treatment are necessary for effective cancer cell killing but the same ROS leads to damaging side effects in normal tissues. Combining antioxidants with chemotherapeutics to alleviate the unwanted side effects produces variable and often undesirable effects on cancer treatment. Here, we describe a more targeted method to improve ovarian cancer cell killing without the need for antioxidants. In ovarian cancer cells, lysophosphatidic acid (LPA) is a prominent growth factor that contributes to tumor survival and proliferation. We find that blocking LPA-dependent signaling with a specific receptor antagonist consistently increases cell death in response to both Taxol and cisplatin. We propose that inhibiting the upregulated growth factor-dependent signaling in cancer cells will target chemo-insensitivity, potentially lowering the necessary dose of the drugs and preventing harmful side effects.
format Online
Article
Text
id pubmed-5767563
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-57675632018-01-18 Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy Rogers, LeAnn C. Davis, Ryan R. Said, Naveen Hollis, Thomas Daniel, Larry W. Redox Biol Research Paper The paradoxical role of reactive oxygen species in cell death versus cell survival establishes a delicate balance between chemotherapy efficacy and management of detrimental side effects. Normal proliferative signaling requires that cells remain inside a redox range that allows reversible protein oxidation to occur. Shifting the redox environment toward highly reducing or oxidizing states leads to cellular stress and cell death. Reactive oxygen species produced in response to Taxol and cisplatin treatment are necessary for effective cancer cell killing but the same ROS leads to damaging side effects in normal tissues. Combining antioxidants with chemotherapeutics to alleviate the unwanted side effects produces variable and often undesirable effects on cancer treatment. Here, we describe a more targeted method to improve ovarian cancer cell killing without the need for antioxidants. In ovarian cancer cells, lysophosphatidic acid (LPA) is a prominent growth factor that contributes to tumor survival and proliferation. We find that blocking LPA-dependent signaling with a specific receptor antagonist consistently increases cell death in response to both Taxol and cisplatin. We propose that inhibiting the upregulated growth factor-dependent signaling in cancer cells will target chemo-insensitivity, potentially lowering the necessary dose of the drugs and preventing harmful side effects. Elsevier 2018-01-04 /pmc/articles/PMC5767563/ /pubmed/29331665 http://dx.doi.org/10.1016/j.redox.2018.01.002 Text en © 2018 Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Rogers, LeAnn C.
Davis, Ryan R.
Said, Naveen
Hollis, Thomas
Daniel, Larry W.
Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy
title Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy
title_full Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy
title_fullStr Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy
title_full_unstemmed Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy
title_short Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy
title_sort blocking lpa-dependent signaling increases ovarian cancer cell death in response to chemotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767563/
https://www.ncbi.nlm.nih.gov/pubmed/29331665
http://dx.doi.org/10.1016/j.redox.2018.01.002
work_keys_str_mv AT rogersleannc blockinglpadependentsignalingincreasesovariancancercelldeathinresponsetochemotherapy
AT davisryanr blockinglpadependentsignalingincreasesovariancancercelldeathinresponsetochemotherapy
AT saidnaveen blockinglpadependentsignalingincreasesovariancancercelldeathinresponsetochemotherapy
AT hollisthomas blockinglpadependentsignalingincreasesovariancancercelldeathinresponsetochemotherapy
AT daniellarryw blockinglpadependentsignalingincreasesovariancancercelldeathinresponsetochemotherapy